BusinessMadrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial HypercholesterolemiaBy Nasdaq OMXSep 19, 2017, 11:30 AM UTC
BusinessMadrigal Pharmaceuticals Reports 2017 Second Quarter Financial ResultsBy Nasdaq OMXAug 10, 2017, 12:50 PM UTC
BusinessAssociates in Cardiovascular Disease and Admera Health Unveiled a Health Economics Model at the 2017 National Lipid Association Conference Detailing the Cost Benefits of Genetic Testing for Familial HypercholesterolemiaBy Nasdaq OMXMay 23, 2017, 1:26 PM UTC
BusinessMadrigal Pharmaceuticals Reports 2016 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Update on Lead Clinical-stage Compound, MGL-3196By Nasdaq OMXApr 3, 2017, 11:30 AM UTC
BusinessAdmera Health Launches Molecular Test for Inherited Early Atherosclerosis Diagnosis and RiskBy Nasdaq OMXMar 17, 2016, 11:00 AM UTC
